Novo Holdings participates in USD 100m financing round of Chinese contractor

Novo Holdings and a syndicate of other investors have injected USD 100m into Chinese contract developer Zhenge Biotech, expanding on Novo Holdings's bet on Asia, which began with the establishment of a new division in Singapore back in 2020.
With the new investment, Novo Holdings continues its efforts within Asia that began back in June 2020 with the establishment of an office in Singapore | Photo: Novo Holdings / PR
With the new investment, Novo Holdings continues its efforts within Asia that began back in June 2020 with the establishment of an office in Singapore | Photo: Novo Holdings / PR
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen

The Novo Nordisk Foundation's  holding company Novo Holdings has once again demonstrated its belief in Asia, this time in the form of an investment in Chinese firm Zhenge Biotech, which is a Contract Development and Manufacturing Organization (CDMO).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading